TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 312 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q1 2021. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $218,761 | +16.3% | 14,141 | +18.1% | 0.00% | +50.0% |
| Q2 2023 | $188,096 | -1.9% | 11,973 | +2.9% | 0.00% | 0.0% |
| Q1 2023 | $191,728 | -35.4% | 11,634 | -49.2% | 0.00% | -50.0% |
| Q3 2022 | $297,000 | -26.8% | 22,884 | -20.9% | 0.00% | -33.3% |
| Q2 2022 | $406,000 | -37.2% | 28,918 | -35.9% | 0.01% | -25.0% |
| Q1 2022 | $646,000 | +54.9% | 45,086 | +47.3% | 0.01% | +60.0% |
| Q4 2021 | $417,000 | +10.9% | 30,602 | +33.5% | 0.01% | 0.0% |
| Q3 2021 | $376,000 | +30.6% | 22,928 | +33.8% | 0.01% | +25.0% |
| Q2 2021 | $288,000 | -36.1% | 17,132 | -30.6% | 0.00% | -33.3% |
| Q1 2021 | $451,000 | +29.6% | 24,696 | +26.6% | 0.01% | +20.0% |
| Q3 2020 | $348,000 | +37.0% | 19,502 | +37.6% | 0.01% | +25.0% |
| Q2 2020 | $254,000 | -33.5% | 14,178 | -26.9% | 0.00% | -33.3% |
| Q4 2019 | $382,000 | -2.1% | 19,386 | -14.6% | 0.01% | 0.0% |
| Q3 2019 | $390,000 | +17.8% | 22,688 | +39.6% | 0.01% | +20.0% |
| Q1 2019 | $331,000 | – | 16,254 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Glenview Capital Management | 16,104,222 | $294,063,000 | 4.98% |
| GMT CAPITAL CORP | 2,468,695 | $45,078,000 | 3.31% |
| MANAGED ASSET PORTFOLIOS, LLC | 1,065,756 | $19,461,000 | 3.13% |
| Blackcrane Capital, LLC | 14,571 | $1,723,000 | 2.72% |
| BFAM Partners (Cayman) Ltd | 328,690 | $6,002,000 | 2.36% |
| Paulson & Co. | 4,727,415 | $86,323,000 | 1.98% |
| Mondrian Investment Partners LTD | 3,510,404 | $59,677,000 | 1.28% |
| Lumbard & Kellner, LLC | 135,550 | $2,264,000 | 0.80% |
| DAVIDSON INVESTMENT ADVISORS | 500,203 | $9,134,000 | 0.78% |
| TFG Asset Management GP Ltd | 589,390 | $10,762,000 | 0.77% |